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SenSory SyStemS DiSorDerS – Clinical outcomes Studies
PSS1
ComParing the effiCaCy of anti-VaSCular enDothelia growth 
faCtor DrugS for treatment of age-relateD maCular Degeneration: 
a CliniCal literature reView anD meta-analySiS
Zhao R., Su W., Carlson A.
University of Minnesota, Minneapolis, MN, USA
Objectives: Review and compare the efficacy of four anti-VEGF (vascular endothelia 
growth factor) drugs for treatment of neovascular age-related macular degenera-
tion (AMD). MethOds: PubMed and clinicaltrials.gov databases were searched to 
identify studies of four anti-VEGF drugs: ranibizumab, bevacizumab, aflibercept, and 
pegaptanib. Eight randomized controlled trials were selected. Fixed-effects model 
was used to pool the data to determine Mantel-Haenszel adjusted relative risk. The 
primary outcome was relative risk (RR) of losing 15 or more letters of visual acuity at 
one year follow-up. The secondary outcome was RR of gaining 15 or more letters of 
visual acuity at one year follow-up. Results: Ranibizumab 0.3 mg or ranibizumab 0.5 
mg significantly reduced the risk of losing 15 or more letters of visual acuity compared 
to sham (RR: 0.15 and 0.13 respectively, p< 0.05). RR of visual acuity gain of 15 letters or 
more was 5.5 for ranibizumab 0.3 mg versus sham (95% CI: 3.5-8.67). The visual acuity 
gain was also significantly higher for ranibizumab 0.5 mg than ranibizumab 0.3 mg 
(RR: 1.24, p< 0.05). There were no significant differences between bevacizumab 1.25 
mg and ranibizumab 0.5 mg in terms of visual acuity loss or gain (RR: 1.17 and 1.04 
respectively, p: 0.46 and 0.69 respectively). Aflibercept 0.5 mg have comparable efficacy 
as ranibizumab 0.5 mg. Pegaptanib reduced the risk of losing 15 letters or more versus 
sham (RR: 0.67, p< 0.05). The RR of gaining 15 or more letters for visual acuity was 3.3 
for pegaptanib versus sham (95% CI: 1.22-7.52). cOnclusiOns: All four anti-VEGF 
drugs reduced the risk of visual acuity loss in patients with AMD. Ranibizumab 0.5 
mg is associated with more visual acuity gain than ranibizumab 0.3 mg. However, 
there is no direct evidence that one treatment is better than the other. More studies 
are needed to compare the efficacy and safety between these drugs.
PSS2
PharmaCologiCal treatmentS in Pregnant women with PSoriaSiS
Lin H.C.1, Hunnicutt J.N.1, Moustafa F.A.2, Rohr A.L.2, Huang K.E.2, Balkrishnan R.3, Feldman S.R.2
1Indiana University, Bloomington, IN, USA, 2Wake Forest University, Winston-Salem, NC, USA, 
3University of Michigan, Ann Arbor, MI, USA
Objectives: Psoriasis treatment in pregnant women requires weighing the risks 
and benefits to both mother and fetus. Little is known about how psoriasis is treated 
during pregnancy. This study sought to identify the medications most commonly 
prescribed in this situation. MethOds: The Truven 2003-2007 MarketScan™ 
Medicaid Database was used. Pregnant women with psoriasis were identified by 
inpatient and outpatient records. The investigators created an algorithm to identify 
eligible pregnant women and approximated their gestational periods using this 
claims database to identify drug use during pregnancies. The prevalence of drug 
use was determined by the proportion of prescriptions. The top 10 most popu-
lar prescriptions as well as methotrexate were identified based on the proportion 
overall and by trimester of pregnancy. Use of topical corticosteroids were revealed 
by drug potency. Results: Based on the algorithm created by the investigators, 
974 pregnant women with psoriasis were identified, and 386 (39.6%) of them filled 
psoriasis drugs and saw a physician for psoriasis before pregnancy. The most com-
mon medications prescribed most patients were topical corticosteroids (n= 122, 
31.6%). Of those patients given topical corticosteroids, the majority were low to 
mid-potency (64.8%). The second most common drug type (n= 41, 10.4%) used was 
“other” products such as topical vitamin-D analogues and pimecrolimus. This was 
followed by biologics (n= 2, 0.5%) and other systemic treatments (n= 2, 0.5%). Two 
patients received methotrexate during their pregnancy- one of which received it 
for the entire gestational period. cOnclusiOns: This study revealed the preva-
lence of psoriasis medications used in pregnant women with psoriasis, which could 
provide information in how risks and benefits of psoriasis treatment in pregnant 
women were weighed. In general, dermatologist prescribing patterns were in line 
with treatment recommendations for pregnant women. However, there were some 
treatments prescribed that were not suitable for pregnant women. Care should be 
to ensure safe treatments for pregnant women.
SenSory SyStemS DiSorDerS – Cost Studies
PSS3
the eConomiC BurDen anD their PreDiCtorS in PreSChool ChilDren 
with Dental CarieS in urBan Beijing
Zhang Y.1, Yang L.2
1Peking University, Beijing, Beijing, China, 2Peking University, Beijing, China
Objectives: Dental caries is associated with poor quality of life and higher 
health care cost. This study aimed to assess the cost of treatment of dental car-
ies of preschool children (3 to 6 years old) and to characterize predictors of these 
costs. MethOds: 194 preschool children were selected by random sampling from 
six kindergarten in urban Beijing. Oral health examinations of these children were 
performed in Stomatological Hospital of Peking University and questionnaires were 
distributed to all tested preschool children’s parents. All information of children’s 
dietary and oral hygiene habits, demographic characters, clinical, parents’oral 
“knowledge, attitudes, and practices” and costs were collected for the analysis. 
We used generalized estimating equations to examine potential predictors of the 
costs. Results: Among 194 dental caries children (mean age = (4.4±1.1) years; 
50% female), the average cost of treatment was RMB718.6 yuan (median:¥400, 
IQR:¥150-¥1000). The multiple linear regressions showed that the treatment cost of 
children with 5 ~ 8 dental caries had 24.2% higher costs than those with 1 ~ 5 dental 
caries;(P< 0.05). The treatment cost of children with more than 8 dental caries had 
47.8% higher costs than those with 1 ~ 5 dental caries; (P< 0.05). cOnclusiOns: 
Objectives: Tobacco smoke is a strong risk factor for chronic obstructive pulmo-
nary disease (COPD), and over 300 million people are estimated to smoke in China. 
This study examined characteristics and treatment patterns of COPD-diagnosed 
patients attempting to quit smoking in urban China. MethOds: National Health 
and Wellness Survey (NHWS) 2010 and 2012 China data were analyzed. NHWS is a 
mixed-methodology, internet-based, nationwide survey of adults (18+ years) strati-
fied by gender and age to represent the demographic composition of urban China. 
Inclusion criteria comprised self-reported diagnosis with COPD and current smokers 
“trying to quit” or non-smokers “in the process of quitting.” Sociodemographics, 
health behaviors, Charlson comorbidity index (CCI) scores (indicating degree of mor-
tality risk), and smoking treatment utilization patterns were assessed. Descriptive 
statistics included percentages/frequencies for categorical variables and means/
standard deviations for continuous variables. Results: Among 1,421 respondents 
diagnosed with COPD, 35.5% (n= 505) were smokers, among which 43.8% (n= 221) 
were currently attempting to quit. Quit attempters were on average 41.1 years old 
(SD= 13.1), male (76.5%), employed (86.9%), 34.8% were overweight/obese, and they 
had been diagnosed with COPD an average 6.9 years (SD= 7.7), with 25.3% report-
ing moderate/severe COPD. Mean CCI was 2.53, 57.5% drank alcohol regularly, and 
30.3% exercised frequently. Many reported smoking as the main cause of their COPD 
(57.5%), followed by illnesses/conditions (53.8%) and pollutants/airborne irritants 
(44.3%). Current smoking was reported by 82.8%, with 14.9% smoking daily. Smoking 
cessation prescription use was reported by 12.7% (n= 28), among whom varenicline 
tartrate was used by 57.1% (n= 16) for an average 20.9 months. Prescription medi-
cations were commonly received from urban/city (50%) or county (35.7%) hospi-
tals. cOnclusiOns: Among COPD patients attempting to quit smoking in urban 
China, few utilized prescription cessation treatments. Given the significant unmet 
need among the high proportion of smokers with COPD, effective smoking cessa-
tion programs are needed.
PrS27
aCCeSS to aSthma meDiCineS in tehran; iran
Ghiasi G.1, Rashidian A.2, Kebriaee A.2, Dorkoosh F.A.1, Salamzadeh J.3
1TUMS, tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran, 3Shahid Beheshti 
University of Medical Sciences, Tehran, Iran
Objectives: Asthma is a chronic disease afflicting more than 300 million people 
throughout the world . Our aim was to examine the availability, pricing and afford-
ability of asthma medicines in Tehran. MethOds: We followed the methodological 
recommendations developed of the World Health Organization and Health Action 
International on measuring medicine prices, availability, affordability and price 
components. Data was collected from a random selection of 30 public sector facili-
ties and 90 private sector retail pharmacies in 22 districts of Tehran in September 
2012. Results: Inhaled Corticosteroids was found in over 25% of the pharmacies. 
The availability of oral corticosteroids and short acting beta agonists was poor in 
all districts of Tehran. Locally manufactured most commonly prescribed medicines 
(beta-agonist and corticosteroid sprays) were affordable as the of cost of one month 
utilization was about 0.3 of one day (equivalent to one day) earning for the unskilled 
worker for the insured (uninsured). However the availability of the asthma medi-
cines were limited and ranged from less than 5% (for the imported sprays) to about 
a third (for the locally manufactured sprays) of the outlets. cOnclusiOns: The 
poor availability of inhalers at public facilities affects those patients who depend 
on these facilities for treatment and medications. In relation with imported asthma 
medicines, results indicate access to asthma medicine has been reduced in most 
medicines, perhaps due to the international sanctions that affected the country in 
2012. Further interventions are required to improve access to asthma medicines at 
the times of financial hardship and international sanctions affecting the ability of 
the importers and producers to provide medicines.
PrS28
eConomiC imPaCt of leValButerol VerSuS alButerol in low-inCome 
PoPulation
Yuan J., Lu K.
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA
Objectives: Short-acting β 2-agonists - albuterol and levalbuterol - are widely pre-
scribed to prevent asthma exacerbations. However, there are significant cost dif-
ferences between the two medications. The objective of this study is, therefore, to 
examine the economic impact of levalbuterol versus albuterol on total health care 
expenditure in a high-risk, low income asthma population. MethOds: A retrospec-
tive cohort study was conducted among asthmatic patients aged 2-64 years old who 
received levalbuterol or albuterol in the South Carolina Medicaid database between 
January 2001 and December 2012. Expenditures were inflated to 2011 dollars using 
the gross domestic product deflator, and adjusted using generalized linear models 
with a gamma distribution and log-link function. Propensity score matching was 
performed to minimize the possible bias related to unbalanced groups. Results: 
A total of 9,370 asthma patients were included in the cohort (levalbuterol: 1,652; 
albuterol: 7,718). The annual spending on levalbuterol was approximately 5 times 
more than albuterol ($272.6 vs. $56.0, p< .001). After adjustment for age, sex, race, 
year of index date, length of asthma, and proportions of days covered by asthma 
control medications, levalbuterol group demonstrated lower asthma-related expen-
ditures on emergency department ($101.3 vs. $143.1, p< .001), hospital ($40.8 vs. 
$85.0, p< .001), outpatient facility ($77.6 vs. $109.1, p< .001) visits, and total health 
care ($386.3 vs. $488.1, p< .001). However, there were no statistically significant 
differences between levalbuterol and albuterol on total health care expenditures 
(levalbuterol: $4041.7 vs. albuterol: $3903.1, p= .41). This nonsignificant difference 
remained when using the propensity score matching method. cOnclusiOns: More 
than 300 million people suffer from asthma worldwide. The use of levalbuterol was 
associated with lower asthma-related costs on ED visits, hospitalizations or outpa-
tient facilities. These cost savings, however, failed to offset the high cost of acquiring 
levalbuterol, suggesting that levalbuterol did not generate greater economic impact 
than albuterol on low-income asthma population.
A782  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  
 effectiveness for lowering IOP compared with latanoprost 0.005% (w/v) and travo-
prost 0.004% (w/v).
PSS7
a literature reView on CoSt-effeCtiVeneSS of treatmentS for wet 
age-relateD maCulare Degeneration
Ying X., Feng S., Lu J., Qi F.
Fudan University, China, Shanghai, China
Objectives: To compare the cost-effectiveness for different therapies to Wet Age-
Related Maculare Degeneration (wAMD) MethOds: Literature Review: Several 
Database, such as Pubmed, Web of Science, Elsevier, Medline were searched using 
16 codes. We applied inclusion criteria to screen the literature. Randomized con-
trolled trials (RCTs), Controlled Clinical Trials (CCTs), and Controlled Before-and-
After studies were selected. This study focus on three commonly interventions to 
wAMD: Best Supportive Case (BSC), PhotoDynamic Therapy (PDT), and Ranibizumab 
therapy. Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and incremen-
tal analysis were conducted. Results: Compare with BSC and PDT, Ranibizumab 
therapy was more effective in wAMD treatment in different countries. From social 
perspective, Ranibizumab therapy was also more cost-effectiveness than BAC and 
PDT either in 5 years or in 10 years. However, from third-payer perspective, incre-
mental cost-effectiveness ratio (ICER) between Ranibizumab and BSC, Ranibizumab 
and PDT, varied in different countries. Frequency and duration of Ranibizumab 
usage may be key determinants of ICER. cOnclusiOns: Ranibizumab therapy have 
better clinical effect than BSC and PDT in wAMD treatment. Ranibizumab is also 
more cost-effectiveness than BSC and PDT from social perspective in long term. 
It may be related to the highly indirect cost of wAMB. However, from third-payer 
perspective, Ranibizumab may be good cost-effectiveness. Price and quantity of 
Ranibizumab in therapy influenced its cost-effectiveness. More research based on 
varied price and different drug usage in Ranibizumab therapy should be conducted 
before it were paid.
PSS8
eConomiC eValuation of BeVaCizumaB VerSuS raniBizumaB in 
neoVaSCular age-relateD maCular Degeneration in China
Li H.1, Li X.2, Xie F.3
1China Pharmaceutical University, Nanjing, China, 2People’s Hospital, Peking University, Beijing, 
China, 3McMaster University, Hamilton, ON, Canada
Objectives: To evaluate the cost-effectiveness of the off-label used bevacizumab 
versus ranibizumab for patients with neovascular age-related macular degenera-
tion (AMD) in China. MethOds: Two different Markov models were used separately 
to compare cost per quality-adjusted life year (QALY) of four strategies defined by 
drug (bevacizumab or ranibizumab) and dosing regimen (monthly or as needed) 
in patients with neovascular AMD in China’s health care system. The VA Range 
model defines the health states using visual acuity (VA), while the VA Change model 
defines the health states according to the degree of VA changes from the time when 
entering the model. Both models used a life time horizon with a cycle length of 3 
months. Clinical data used in the models primarily came from the Comparison of 
AMD Treatment Trial (CATT), while the costs came from the financial department of 
a tertiary hospital in Beijing. Results: In the base-case analyses, the bevacizumab 
as needed strategy had slightly lower QALYs (17.479 QALYs and 15.917 QALYs in 
the VA Range model and the VA Change model, respectively) but at much lower 
costs (CN¥88,341 and CN¥79,967 in the VA Range model and the VA Change model, 
respectively) compared with the other three strategies. In probabilistic sensitivity 
analyses in both models, the probabilities of bevacizumab strategies being more 
cost-effective than ranibizumab strategies exceeded 99% if the willingness-to-pay 
(WTP) threshold for a QALY was less than CN¥120,000. When the threshold was less 
than CN¥90,000 per QALY, bevacizumab as needed was the most cost-effective alter-
native. cOnclusiOns: The bevacizumab as needed strategy was the most cost-
effective strategy compared with the ranibizumab strategies in treating patients 
with neovascular AMD, if the WTP threshold is below CN¥90,000 per QALY in China. 
This much cheaper treatment can substantially reduce the burden to the Chinese 
aging society.
PSS9
CoSt utility analySiS of uStekinumaB for the treatment of 
moDerate to SeVere ChroniC Plaque PSoriaSiS in thailanD
Tangwongsiri D.1, Leartsakulpanitch J.2
1Janssen-Cilag (Thailand) Limited, Bangkok, Thailand, 2Janssen Asia Pacific, Singapore
Objectives: To evaluate the cost-utility of ustekinumab versus infliximab and 
etanercept, the only biologic agents available for psoriasis in Thailand, among 
adults with moderate-to-severe plaque psoriasis who fail to respond systemic 
therapies and meet criteria based on the biologic guideline for psoriasis in 
Thailand. MethOds: The published ‘York psoriasis model’ was modified based 
on the current treatment algorithm and criteria of biologics use in Thai psoriasis 
guideline. Short-term trial efficacy data (PASI response) from a published network 
meta-analysis of RCT was used to model the response of patients to initial treat-
ment. Beyond the initial period, the model extrapolated results up to 10 years with 
annual risk of treatment withdrawal. The DLQI scores from ustekinumab trials were 
transposed into utility gain (EQ5D) and applied to PASI response level regardless of 
the treatment received. Both direct medical cost and non-medical cost including 
biologic acquisition, monitoring lab tests, outpatient visit, and traveling expense 
were calculated. The amount of resource consumption was estimated by experts’ 
opinions and literatures. Cost and outcomes were discounted at 3%. One-way 
and probabilistic sensitivity analysis was conducted to assess the model robust-
ness. Results: Over the 10-year time horizon, ustekinumab showed the lowest 
mean annual cost of 507,502 baht followed by etanercept (582,881 baht) and inflixi-
mab (585,462 baht) respectively. The mean QALY gain of ustekinumab was higher 
than etanercept (0.1448 vs. 0.1392) but lower than infliximab (0.1448 vs. 0.1564). 
Considering the cost-utility ratio, ustekinumab was dominant compared to etaner-
Preschool children with dental caries is associated with high treatment costs and 
the number of cavities play an important role in determination of costs. Therefore, 
preschool children should pay attention to oral hygiene and form good habits to 
prevent dental caries.
PSS4
BurDen of wet age-relateD maCular Degeneration in China
Zhang Y.1, Hu S.2, Chang J.3
1shanghai Institution of Technolocy, Shanghai, China, 2Shanghai Bureau of Health, Shanghai, 
China, 3Beijing Novartis Pharma Co., Ltd, Beijing, China
Objectives: To explore the burden of wet age-related macular degeneration 
(WAMD) in China. MethOds: Multi-center, retrospective and cross-sectional inves-
tigation was adopted. Beijing, Chengdu, Guangzhou and Shanghai were selected 
as sample cities, and several hospitals were involved in each city. Patients were 
selected according to inclusive and exclusive criteria, and they were divided into 5 
groups, i.e., photodynamic therapy (PDT), photocoagulation therapy, surgery therapy, 
joint therapy and support therapy groups. Direct cost, indirect cost and burden of 
disease (BOD) were studied. Results: 417 eligible patients were acquired, males 
and females accounted for 51.32% and 48.68% respectively. Burden of WAMD for 
per eye per year was 4857 USD. Burden of WAMD of whole disease course for each 
eye was 33999 USD. The proportion of direct medical cost in BOD was only 26.35%, 
however, that of indirect cost reached 68.58%. cOnclusiOns: The burden of 
WAMD is relatively high in China, it should be paid more attention by stakehold-
ers. Although new diagnostic and therapeutic methods may raise direct medical 
cost, they may reduce total burden of  WAMD more, which shows the advantage for 
new technologies. WAMD guideline will be beneficial to both patients and direct 
medical cost management. Targeting young patients as a priority of intervention 
will help to reduce total social burden of  WAMD.
PSS5
CoSt-effeCtiVeneSS analySiS of latanoProSt ComPareD with 
DorzolamiDe/timolol fixeD ComBination for the treatment of oPen-
angle glauComa anD oCular hyPertenSion PatientS in korea
Lee Y., Park D.J., Ko S.K.
Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
Objectives: Glaucoma is a major cause of visual impairment and a chronic dis-
ease requiring treatment for lifetime. Management of intraocular pressure (IOP) 
is the main focus of treatment, and many pharmacological treatment agents are 
recommended and available in Korea. This study was conducted to facilitate effi-
cient allocation of limited resources amongst various pharmacological agents. The 
objective of this study was to evaluate costs and effectiveness of two most com-
monly used drugs in Korea which are latanoprost and dorzolamide/timolol fixed 
combination. MethOds: A decision analytic model was developed from a payer 
perspective to evaluate clinical effectiveness, costs and utility values of latanoprost 
and dorzolamide/timolol fixed combination. The model was constructed based on a 
one-month cycle with a time horizon of one year. The treatment success to meas-
ure effectiveness was defined as achieving a ≥ 20% reduction IOP from baseline. 
Costs of medication, diagnostic fees, physician and pharmacy visitation fees, and 
surgery fees were included in the study. Utility values according to the severity 
of glaucoma were also incorporated in the model. Treatment success and failure 
rates as well as utility for each health state were obtained from previously pub-
lished literature and local market analysis data. Cost information was obtained 
from Korea-specific data sources. The result of this study was expressed in an 
incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis was con-
ducted to evaluate different clinical parameters. Results: The final effectiveness 
values for latanoprost and dorzolamide/timolol fixed combination were 0.9098 and 
0.9089 in quality-adjusted life year (QALY), and the final costs were 550,737 KRW 
and 534,789 KRW respectively. Latanoprost displayed an ICER of 17,500,246 KRW/
QALY compared to dorzolamide/timolol fixed combination. cOnclusiOns: Under 
the currently implied ICER threshold in Korea, latanoprost can be interpreted as a 
cost-effective treatment option compared to dorzolamide/timolol fixed combination 
on the treatment of glaucoma.
PSS6
a ProSPeCtiVe PharmaCoeConomiC StuDy of Bilateral 
ProStaglanDin/ ProStamiDe theraPy for lowering intraoCular 
PreSSure (ioP) in the PatientS in South inDia
Addanki D.
Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India
Objectives: To determine monthly cost and cost effectiveness of bilateral prosta-
glandin/ prostamide therapy for lowering intraocular pressure (IOP) in patients tak-
ing bimatoprost (0.03%), latanoprost (0.005%), or travoprost (0.004%). MethOds: 
This prospective pharmacoeconomic study evaluated the direct cost and cost effec-
tiveness of prostaglandin/prostamide therapy for reduction of IOP in patients with 
glaucoma or ocular hypertension. Drops in five new 2.5-mL bottles were counted 
and then averaged for each drug. Average retail price was determined by surveys 
of pharmacies. Drop count, average retail price, average wholesale price, and IOP 
reduction data were used to compute annual cost, and cost effectiveness (annual 
cost-per-mm Hg of IOP reduction) of the three drugs. Results: Drops per 2.5-mL 
bottle averaged 113 for bimatoprost 0.03% (w/v), 84 for latanoprost 0.005% (w/v), and 
83 for travoprost 0.004% (w/v). Average retail cost (2005) per bottle was INR.3,080 
for bimatoprost 0.03% (w/v), INR.2,715 for latanoprost 0.005% (w/v), and INR.2,920 
for travoprost 0.004% (w/v). The monthly retail cost of bilateral therapy was 
INR.1,668 for bimatoprost 0.03% (w/v), INR.1,970 for latanoprost 0.005% (w/v), and 
INR.2,167 for travoprost 0.004% (w/v). Cost effectiveness ranges were INR.2,508 
to INR.2,860 per mm Hg reduction in IOP per year for bimatoprost, 0.03% (w/v), 
INR.2,948 to INR.3,960 per mm Hg for latanoprost 0.005% (w/v), and INR.3,256 to 
INR.3,696 per mm Hg for travoprost 0.004% (w/v). cOnclusiOns: Bimatoprost 
0.03% (w/v) had the lowest monthly and annual costs and the greatest cost 
